Research
Hormonal
Statin therapy is the first-line treatment for dyslipidemia in type 2 diabetes, significantly reducing cardiovascular events, although it only modestly lowers triglycerides.
Take your prescribed statin daily. It is the most effective tool for preventing heart attacks and strokes in type 2 diabetes. While it may not lower triglycerides drastically on its own, it is essential for your overall cardiovascular health.
StrongSupportsVERY_HIGH confidence
Statin therapy is the cornerstone of treatment of dyslipidemia in diabetes... Large statin outcome trials have supported its use in reducing coronary events and mortality.
Why this rating
Supported by multiple large outcome trials (55-58) and subgroup analyses specifically in diabetics.
Source
Origin and therapy for hypertriglyceridaemia in type 2 diabetes
Jing Pang et al. · World Journal of Diabetes · 2014
DOI 10.4239/wjd.v5.i2.165
narrative_reviewCited 23×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Niacin is no longer recommended for routine use in type 2 diabetes because large clinical trials failed to show significant cardiovascular benefits despite improving lipid parameters.Strong
- Modest weight loss (5%-10%) in type 2 diabetes significantly lowers plasma triglyceride levels (up to 25%) and normalizes postprandial triglyceride concentrations.Good
- Fibrates (specifically fenofibrate) are effective adjunctive treatments for lowering triglycerides and reducing cardiovascular events in type 2 diabetic patients with high triglycerides and low HDL.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →